| |
Thirty
six women suffering from symptoms of dysfunctional uterine bleeding
were selected for trial with EveCare Syrup, a polyherbomineral formulation.
EveCare Syrup was administered at a dose of 2 teaspoonsful, twice
daily for 3 months.
56.6%
of the women were completely cured and 33.3% had partial relief.
No side effects were observed during the study. Thus, EveCare Syrup
is effective in controlling dysfunctional uterine bleeding and regularizing
the menstrual cycle.
Every
healthy woman menstruates regularly and rhythmically every month
during her reproductive era. The menstrual cycle is significant
in the fertility of a woman. Any abnormality may put the woman in
distress. The regularity of menstruation depends upon hypothalamo-pituitary-ovarian
function, whereas, the amount of blood loss depends upon the uterine
condition.
About
28% of women consider their menstrual loss excessive and plan their
activities around their menstrual cycle and nearly 10% of employed
women take time off from work due to excessive loss1.
Six percent of women between 25-44 consult their family physician
for excessive loss every year2. Among 35% of these are
referred to hospitals3 and 60% will go in for a hysterectomy
in the next 5 years4. Over 7500 hysterectomies are carried
out every year with 30% of them for menstrual disturbances5.
The exact pathophysiology is difficult to understand and hence the
disorder is broadly referred as dysfunctional uterine bleeding.
According
to Kistner, in cases of dysfunctional uterine bleeding, 57.5% had
a normal endometrium, in 30.8% of cases hyperplasia of the endometrium
was observed, the incidence of irregular ripening and irregular
shedding was present in 7.8% and atrophy was seen in 3.9% of the
cases6.
Various
treatments prescribed in modern medicine like hormone therapy, anti-prostaglandins
and antifibrinolytic agents have not proved their definite efficacy.
In Ayurveda, a number of herbal drugs have been mentioned which
are very effective in menstrual disorders.
EveCare
Syrup, a uterine tonic was formulated containing extracts of different
herbs by The Himalaya Drug Company, Bangalore. An open clinical
trial was conducted to evaluate its efficacy in dysfunctional uterine
bleeding.
Patients
attending the out patient department of Prasuti Tantra, S.S Hospital,
Varanasi were selected at random with complaints of abnormal and
excessive vaginal bleeding for more than 3 consecutive cycles. Thirty
six women were enrolled in the trial.
Inclusion
criteria
Patients
who complained of excessive irregular/prolonged bleeding per
vaginum.
Patients
who did not use oral contraceptive pills, hormonal treatment
or IUCDs.
Patients
who had no systemic illness like hypertension, renal disease,
tuberculosis, hepatic disease, diabetes, coagulation disorder,
etc.
Patients
who had no organic lesion of the reproductive tract especially
any benign or malignant growth, extensive cervical erosion,
cervical polyps, endometriosis, tubercular endometritis and
acute infective disorder.
Patients
having Hb³ 8 gm% (to avoid severe anaemia leading to blood loss).
Patients
whose history excluded recent delivery or abortion.
All
the women had complete physical and gynecological examinations along
with screening for haemogram bleeding, clotting time and platelet
count.
Drug
Dose Schedule and Subjective Assessment
Patients
were given EveCare Syrup, at a dose of 2 teaspoonsful twice daily
for 3 months. All the patients were reviewed at regular intervals
of one month for three months for subjective assessment.
Method
of Scoring
To
facilitate the data recording of proforma, the scoring of various
symptoms were done as follows:
Amount
of Blood Loss
This
was assessed on the basis of statements given by patients. Each
case was asked the day when maximum bleeding took place as it varies
from person to person. Hence the number of sanitary pads used on
the day of maximum bleeding was recorded. Women were advised to
use standard size sanitary pads i.e. 6" x 3" x 1.5"
of average weight made of cotton.
Amount No.
of sanitary pads used/day Score
Normal 3-4 1
Excessive 5-6
2
Very excessive
7 and above 3
Duration
of Menstrual Cycle
Cases
were asked for the duration of bleeding in the number of days in
a month.
Duration
No. of days Score
Normal
2-3 1
Prolonged
4-6 2
Very
prolonged 7 and above 3
Intermenstrual
Interval
Interval
No. of days Score
Normal
interval 26-30 1
Early
periods 21-25 2
Frequent
15-20 3
Cure
Score
At
the end of 3 follow ups, patients were assessed again on the basis
of the change towards normalcy in amount, duration, and intermenstrual
interval and improvement in associated symptoms.
Complete
Relief
·
Normal amount of blood loss
·
Normal duration of blood loss
·
Normal interval between the cycles
·
Normal consistency of menstrual blood
·
Relief in associated symptoms
Partial
Relief
Cases
having any 2 of the above criteria with relief in associated symptoms
Unchanged
No
improvement in any of the above criteria
Statistical
analysis
The
students paired t-test was applied to evaluate the significant
difference within a group. The Z-test was also used to evaluate
the significant difference between the initial and follow up periods
after treatment.
The
factors responsible for dysfunctional uterine bleeding are:
Tension,
anxiety or emotional factors7,8.
Infections
of the uterus and adenaxae9.
Inflammation
of the uterus and adenaxae10.
Hormonal
imbalance11.
Fibrinolytic
activity12.
Delayed
endometrial regeneration13.
Menorrhagia
may be associated with nausea, loss of appetite, backache, anxiety,
oedema, bodyache, general weakness and anaemia.
In
the trial, all the patients enrolled were in their reproductive
years. The youngest patient in the study was of 18 years and the
eldest was 42 years with a mean of 27.4 ± 7.4 years.
Frequency
distribution of age at menarche is given in Table 1.
|
Table
1: Age, frequency, percentage
|
|
Age
|
Frequency
|
Percentage
|
|
12
|
1
|
3.3
|
|
13
|
7
|
23.3
|
|
14
|
7
|
23.3
|
|
15
|
2
|
6.7
|
|
16
|
4
|
13.3
|
|
18
|
2
|
6.7
|
|
20
|
2
|
6.7
|
|
Missing
|
5
|
16.7
|
|
Total
|
30
|
100.0
|
The
frequency distribution of gravida, parity and abortion is given
in Tables 2, 3 and 4, respectively.
Percentage
of dysmenorrhoea, duration of bleeding and quantity of bleeding
are described in Tables 5, 6 and 7, respectively.
|
Table
2: Gravida
The gravidity of these women ranged
from 0.9 with a M(SD) of 2.7 (2.2). The frequency distribution
of gravidity is presented below:
|
|
Gravida
|
Frequency
|
Percentage
|
|
0.00
|
5
|
16.7
|
|
1.00
|
2
|
6.7
|
|
2.00
|
4
|
13.3
|
|
3.00
|
4
|
13.3
|
|
4.00
|
4
|
13.3
|
|
5.00
|
3
|
10.0
|
|
9.00
|
1
|
3.3
|
|
Missing
|
7
|
23.3
|
|
Total
|
30
|
100.0
|
|
Table 3: Parity
The parity of the women ranged from 0 to 9 with a M(SD)
of 2.6 (2.1). The frequency distribution of parity is presented
below:
|
|
Para
|
Frequency
|
Percentage
|
|
0.00
|
4
|
13.3
|
|
1.00
|
2
|
6.7
|
|
2.00
|
6
|
20.0
|
|
3.00
|
5
|
16.7
|
|
4.00
|
3
|
10.0
|
|
5.00
|
2
|
6.7
|
|
9.00
|
1
|
3.3
|
|
Missing
|
7
|
23.3
|
|
Total
|
30
|
100.0
|
|
Table
4: Abortions
The abortions of the women ranged
from 0 to 2 with a M(SD) of 0.8 (1.0). The frequency distribution
of parity is presented below:
|
|
Abortion
|
Frequency
|
Percentage
|
|
0.00
|
2
|
6.7
|
|
1.00
|
1
|
3.3
|
|
2.00
|
1
|
3.3
|
| Missing |
26
|
86.7
|
| Total |
30
|
100.0
|
|
Table
5: Dysmenorrhoea
The incidence of dysmenorrhoea at
baseline and at each monthly assessment is presented below:
|
|
Time
point
|
No.
|
Percentage
|
|
Baseline
|
27
|
90
|
|
Month
1
|
23
|
76.7
|
|
Month
2
|
14
|
46.7
|
|
Month
3
|
10
|
33.3
|
|
Thus,
it is clear that there was a >50% drop in the number of
women who complained of dysmenorrhoea; most women who responded
did so between one and two months of treatment.
|
|
Table
6: Duration of bleeding
The duration of bleeding (in days)
during the periods is presented below.
|
|
Time
point
|
Mean
|
Std
Dev.
|
Minimum
|
Maximum
|
N
|
|
Baseline
|
5.63
|
2.75
|
0
|
12
|
30
|
|
Month
1
|
5.00
|
1.44
|
3
|
8
|
30
|
|
Month
2
|
4.87
|
1.50
|
3
|
8
|
30
|
|
Month
3
|
4.84
|
1.57
|
2
|
8
|
25
|
|
(Data
from 5 women were missing from the last time point). Although
the duration of bleeding decreased progressively from baseline
to month 3, the decrease was not statistically significant
(Pillais trace=0.21, F=2.01, df=3,22, p=0.14).
It is possible that the results may have been significant
had the sample been larger.
|
|
Table
7: Quantity of bleeding
The quantity of bleeding during
each menstrual period presented in terms of pads changed per
day, is shown below:
|
|
Time
point
|
Mean
|
Std
Dev.
|
Minimum
|
Maximum
|
N
|
|
Baseline
|
4.35
|
2.39
|
2
|
9
|
20
|
|
Month
1
|
4.61
|
1.90
|
2
|
9
|
23
|
|
Month
2
|
4.61
|
1.95
|
2
|
9
|
23
|
|
Month
3
|
4.68
|
2.03
|
2
|
9
|
19
|
|
Complete
data for all time points was available for only 13 women.
There was no significant change across time in the number
of pads changed daily during the menstrual period (Pillais
trace=0.44, F=2.62, df=3,10, p=0.11).
|
The
duration of cycle, reduced cycle, regular cycles and intermenstrual
bleeding are shown in Tables 8, 9, 10 and 11, respectively.
|
Table
8: Duration of cycle
The duration of the menstrual cycle
(in days) at each time point of assessment is presented below:
|
|
Time
point
|
Mean
|
Std
Dev
|
Minimum
|
Maximum
|
N
|
|
Baseline
|
27.24
|
6.28
|
12
|
40
|
21
|
|
Month
1
|
27.79
|
3.92
|
20
|
38
|
28
|
|
Month
2
|
27.86
|
2.20
|
22
|
32
|
29
|
|
Month
3
|
27.83
|
1.93
|
22
|
30
|
29
|
|
There
was no significant change across time (Pillais trace=0.02,
F=0.10, df=3,18, p=0.96).
|
|
Table
9: Reduced cycles
The incidence of reduced cycles
at each time point of assessment is presented below:
|
|
Time
point
|
No.
|
Percentage
|
|
Base
line
|
15
|
50.0
|
|
Month
1
|
7
|
23.3
|
|
Month
2
|
4
|
13.3
|
|
Month
3
|
1
|
3.3
|
|
Most
of the women who improved, showed improvement within the first
month of treatment.
|
|
Table
10: Irregular cyclical bleeding
The incidence of irregular cyclical
bleeding at each time point of assessment is presented below:
|
|
Time
point
|
No.
|
Percentage
|
|
Baseline
|
8
|
26.7
|
|
Month
1
|
3
|
10.0
|
|
Month
2
|
3
|
10.0
|
|
Month
3
|
3
|
10.0
|
|
As
previously noted, most of the women who improved, showed improvement
within the first month of treatment.
|
|
Table
11: Intermenstrual bleeding
The incidence of intermenstrual
bleeding at each time point of assessment is presented below:
|
|
Time
point
|
No.
|
Percentage
|
|
Baseline
|
1
|
3.3
|
|
Month
1
|
1
|
3.3
|
|
Month
2
|
0
|
0.0
|
|
Month
3
|
0
|
0.0
|
|
As
with other features, most women who improved showed improvement
within the first month of treatment.
|
There
was a significant decrease in the overall severity of menstrual
symptoms (Table 12).
|
Table 12: Overall
improvement in symptoms
In order to ascertain the overall improvement in the clinical
picture, composite (total) scores were computed at each time
point by summing the ratings for dysmenorrhoea, reduced cycles,
irregular cyclical bleeding and intermenstrual bleeding at
each time point. For this purpose, each symptom was rated
as 0 if absent and 1 if present.
The total scores
are presented below:
|
|
Time
point
|
Mean
|
Std
Dev
|
Minimum
|
Maximum
|
N
|
|
Baseline
|
1.70
|
0.75
|
1.00
|
4.00
|
30
|
|
Month
1
|
1.14
|
0.58
|
0.00
|
2.00
|
29
|
|
Month
2
|
0.69
|
0.81
|
0.00
|
2.00
|
29
|
|
Month
3
|
0.55
|
0.74
|
0.00
|
2.00
|
29
|
|
There
was a statistically significant decrease in overall severity
of menstrual symptoms across time (Pillais trace=0.62,
F=13.87, df=3,25, p<0.001).
|
Age
was unrelated to response at any time, which suggests that women
of all ages responded to EveCare Syrup treatment (Table 13).
Overall,
the amount of excessive blood loss was reduced significantly. There
was no intermenstrual bleeding and menstrual cycles were regularized
during the next 3 months (Table 14).
|
Table 13: Age
and response
In order to ascertain the relationship between age and
response, Pearsons correlation coefficients were derived
between age and the total score at each assessment point.
These coefficients are presented below:
|
|
Correlations
|
Age
|
TOT0
|
TOT1
|
TOT2
|
TOT3
|
|
Age
|
1.0000
|
-0.1378
|
-0.1457
|
-0.0253
|
-0.0472
|
|
From the correlation
coefficients, it is clear that age was unrelated to response
at any time point; in other words, women of all ages can be
expected to respond to EveCare Syrup.
|
|
Table 14: Showing
change in duration, amount of blood loss and intermenstrual
period before starting the treatment and in subsequent follow-ups
with statistical analysis.
|
| Blood
loss |
Initial
|
1st
FU
|
2nd
FU
|
3rd
FU
|
Z
value
|
|
Normal
|
8
(26.66%)
|
19
(63.3%)
|
20
(66.6%)
|
21
(70%)
|
3.8***
|
|
Excessive
|
1
(36.66%)
|
8
(26.665%)
|
6
(20%)
|
6
(20%)
|
1.45*
|
|
Very
excessive
|
11
(36.66%)
|
3
(10.0%)
|
4
(13.33%)
|
3
(10%)
|
2.58**
|
|
Duration
of menstrual cycle
|
|
Normal
|
5
(16.6%)
|
13
(43.3%)
|
16
(53.33%)
|
19
(63.33%)
|
4.23***
|
|
Prolonged
|
12
(40%)
|
12
(40%)
|
10
(33.33%)
|
7
(23.33%)
|
1.44*
|
|
Very
prolonged
|
13
(43.3%)
|
5
(16.6%)
|
4
(13.33%)
|
4
(13.33%)
|
2.74**
|
|
Intermenstrual
interval
|
|
Normal
|
14
(46.66%)
|
20
(66.6%)
|
24
(80%)
|
24
(80%)
|
2.84**
|
|
Early
|
7
(23.33%)
|
7
(23.33%)
|
6
(20%)
|
6
(20%)
|
0.28*
|
|
Frequent
|
9
(30%)
|
3
(10%)
|
0
(0%)
|
0
(0%)
|
3.61***
|
|
*
No Significant, **p<0.01, ***p<0.001
|
An
open clinical trial of EveCare Syrup, a polyherbal formulation produced
significant symptomatic relief in women with dysfunctional uterine
bleeding. The various constituents of EveCare Syrup are known in
Ayurveda for their benefits in various menstrual disorders including
dysfunctional uterine bleeding.
Saraca
indica14 has been well proven for its effectiveness
in menorrhagia and dysmenorrhoea. It also has a stimulatory effect
on the ovarian tissue which may produce an oestrogen-like activity
that enhances the repair of the endometrium and stops bleeding.
Symplocos racemosa15 has been reported to be useful
in the treatment of menorrhagia and other uterine disorders. The
ethanolic extract of Boerhaavia diffusa16 was
found to stop intra-uterine-contraceptive-device-induced bleeding
in monkeys. This herb is also known for its anti-inflammatory and
analgesic property which is comparable to that of ibuprofen. The
drug has also proved useful as a haematinic. Symplocos racemosa17
exhibit relaxant and antispasmodic effects on several spasmogens
on uterine smooth muscles, attributing favorable actions to the
drug in dysmenorrhoea and as a uterine sedative. Cyperus rotundus18
has been utilized in the treatment of anaemia and general weakness.
Aloe vera19 also possesses oxytocic property.
Taking
into consideration the results of the trial and the proven reports
of the herbs used in the formulation, it can be concluded that EveCare
Syrup can effectively control dysmenorrhoea, the manifestation of
dysfunctional uterine bleeding.
In
the first follow up, 43.3% cases showed normal duration, 63.3% reached
the normal amount and 46.66% had a normal intermenstrual period.
In the third follow up, 70% of the cases had normal blood loss,
63.33% cases had normal duration and 80% had normal intermenstrual
period.
On
the basis of the cure score mentioned earlier, in the
present study 56.6% (17 cases) were completely cured, 33.3% (10
cases) had partial relief and 10% (3 cases) remained unchanged.
No
side effects were observed. Along with normalizing bleeding per
vaginum, which is excessively significant, relief in associated
symptoms also contributed to the efficacy of this trial drug.
- Edlund M,
Magnusson C and Von Schoultz B. Quality of life a Swedish survey
of 2200 women. In: Dysfunctional Uterine Bleeding. Smith
SK (Ed.) Royal Society of Medicine Press, London 1994;pp. 36-37.
- Royal College
of General Practitioner and the office of population surveys.
Morbidity Statistics from G.P. 1981-82; HM50, London 1986.
- Coutter A,
Peto V and Doll H. Patients preference and G.P.s decision
in the treatment of menstrual disorders. Farm. Prac. 1994;11:67-74.
- Outcomes
of referral to gyn. Out patient clinic for menstrual problem:
An audit of GP records. Br. J. Obstet. Gynecol. 1991;98:789-796.
- Soc. Sci.
Med. 1988;27:987-994.
- Kistner
R. Gynecology Principle and Practical yearbook. Chicago,
IL 1964;238.
- Smith
Fremont and Meigi JV. Menstrual dysfunction due to emotional
factor. Am. J. Obstet. Gynec. 56:1037-1048.
- Devi PK
and Suteria. J. Obstet. Gynec. 1964;14:353.
- Disorders
of menstruation. Shaws Textbook of Gynecology 2nd
Edition. 320.
- Disorders
of menstruation. Dawn Textbook of Gynecology 4th
Edition, 1976.
- Haynes PJ,
Anderson ABM and Turbull AC. Endocrine studies in unexplained
menorrhagia. Res. Clin. Forum 1979;1:73-78.
- Bonnar J,
Shappard BL and Dockerey CJ. The hemostatic system and dysfunctional
uterine bleeding. Research Clinical Forum 1983;5:27-36.
- Dewhursts
Textbook of Obstetrics & Gynecology for Postgraduates 5th
Edition 1995;590.
- Satyavati
GV. Further studies on the uterine activity of Saraca indica
Linn. Ind. J. Med. Res. 1970;58:947.
- Kirtikar
KR and Basu BD. Ind. Med. Plant International Book Distribution,
Dehradun, India 1987;II:1511.
- Lami, et
al. Chem. Pharm. Bull. 1990;38:1558.
- Hussain A,
et al. Dictionary of Ind. Med. Plants 1982;CMAP:25.
- Kirtikar
KR and Basu BD. Ind. Med. Plant International Book Distribution,
Dehradun, India 1987:IV:1010.
- Hussain A,
et al. Dictionary of Ind. Med. Plants 1982;CMAP:444.
|
 |